Investors searching for high-quality opportunities in the pharmaceutical space should keep a close eye on stocks trading at extremely oversold levels. One of the most popular ways to measure this is through the Relative Strength Index (RSI), a technical momentum indicator that signals when a stock may be due for a rebound. An RSI below 30 suggests a stock is extremely oversold and could be primed for a bounce, especially if sentiment is showing signs of turning or if the stock has retained analyst support.
Right now, three pharma names stand out with RSIs at this level: Sarepta Therapeutics, Krystal Biotech, and Lantheus Holdings. All three have been under pressure following earnings misses or weak guidance. Still, their technical setups, analyst support, and long-term outlooks suggest potential upside for those ready to buy the dip.
